CD274 and hepatocellular carcinoma: With the publication of this global, open-label, phase III randomized trial, the combination of the PD-L1 inhibitor, atezolizumab, and the anti-VEGF monoclonal antibody, bevacizumab, was highly expected as a novel strategy for unresectable HCC treatment (Finn et al., 2020c).